FDA Approves GFH925 (KRAS G12C Inhibitor) Monotherapy trial in Ph 3 Registrational Study Treating Metastatic CRC
“We appreciate the FDA’s recognition of GFH925′ efficacy and safety profile, as this is our first global phase III monotherapy study in treating advanced stage CRC. We believe the approval of our proposed trial design highlights the potential of GFH925 monotherapy in this indication, thus bringing more therapeutic options and clinical benefits to the patients. This is a significant step forward in the development of GFH925, paving the way for its potential future use as a front-line treatment for CRC. “stated Yu Wang, Ph.D/M.D., Chief Medical Official of GenFleet. “Additionally, the study of GFH925 in combination with cetuximab is ongoing in Europe treating advanced NSCLC in the first-line setting and the phase II trial has completed the enrollment; the preliminary data analysis of this combination study, accepted as a late breaking abstract, has been selected for oral presentation during the 2024 ASCO annual meeting. GFH925’s global development reflects GenFleet’s forward-thinking strategy, the expertise of our clinical team and the deep understanding of biology for our RAS-targeted pipeline.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the